Zolpidem and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data

Summary:

Paranasal sinus hypersecretion is reported as a side effect among people who take Zolpidem (zolpidem tartrate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Myrbetriq, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Paranasal sinus hypersecretion when taking Zolpidem. It is created by eHealthMe based on reports of 90,339 people who have side effects when taking Zolpidem from the FDA, and is updated regularly.

What is Zolpidem?

Zolpidem has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 92,695 Zolpidem users. Check the latest studies of Zolpidem.

What is Paranasal sinus hypersecretion?

Paranasal sinus hypersecretion is found to be associated with 438 drugs and 463 conditions by eHealthMe. Check the latest studies of Paranasal sinus hypersecretion.

On Jul, 19, 2026

90,339 people reported to have side effects when taking Zolpidem.
Among them, 24 people (0.03%) have Paranasal sinus hypersecretion.

Could Zolpidem cause Paranasal sinus hypersecretion?

Among these 24 people:

How long have people been on Zolpidem when they have Paranasal sinus hypersecretion? *

What is the gender of people who have Paranasal sinus hypersecretion when taking Zolpidem? *

female: 77.27 %
male: 22.73 %

What is the age of people who have Paranasal sinus hypersecretion when taking Zolpidem? *

What are other drugs people take besides Zolpidem? *

What are other side effects people have besides Paranasal sinus hypersecretion? *

Cough: 8 people, 33.33%
Fatigue (feeling of tiredness): 8 people, 33.33%
Oropharyngeal Pain: 7 people, 29.17%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 7 people, 29.17%
Weight Decreased: 6 people, 25.00%
Dyspnea (difficult or laboured breathing): 6 people, 25.00%
Fall: 6 people, 25.00%
Sinusitis (inflammation of sinus): 5 people, 20.83%
Asthma: 5 people, 20.83%
Productive Cough: 5 people, 20.83%

What are the existing conditions these people have? *

Asthma: 5 people, 20.83%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 20.83%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 16.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 16.67%
Blood Pressure Abnormal: 3 people, 12.50%
Primary Immunodeficiency Syndrome: 3 people, 12.50%
High Blood Cholesterol: 3 people, 12.50%
High Blood Pressure: 3 people, 12.50%
Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 3 people, 12.50%
Irritable Bowel Syndrome: 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Zolpidem and have Paranasal sinus hypersecretion?

- Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zolpidem:

Zolpidem (92,695 reports)

Browse all side effects of Zolpidem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (438 drugs)

Browse all the conditions that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (463 conditions)

Related publications that referenced our studies

Hsu FG, Sheu MJ, Lin CL, Hsieh YW, Lai SW, "Use of Zolpidem and Risk of Acute Pyelonephritis in Women: A Population‐Based Case‐Control Study in Taiwan", The Journal of Clinical Pharmacology, 2017 Mar .
Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH, "Association between zolpidem and suicide: a nationwide population-based case-control study", InMayo Clinic Proceedings, 2016 Mar .
Liao KF, Lin CL, Lai SW, Chen WC, "Zolpidem use associated with increased risk of pyogenic liver abscess: a case-control study in Taiwan", Medicine, 2015 Jan .
Hsu FG, Sheu MJ, Lin CL, Hsieh YW, Lai SW, "Use of Zolpidem and Risk of Acute Pyelonephritis in Women: A Population‐Based Case‐Control Study in Taiwan", The Journal of Clinical Pharmacology, 2017 Mar .
Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH, "Association between zolpidem and suicide: a nationwide population-based case-control study", InMayo Clinic Proceedings, 2016 Mar .
Liao KF, Lin CL, Lai SW, Chen WC, "Zolpidem use associated with increased risk of pyogenic liver abscess: a case-control study in Taiwan", Medicine, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on zolpidem tartrate (the active ingredients of Zolpidem) and Zolpidem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.